The American Journal of Medicine
Volume 120, Issue 2, Supplement 1 , Pages S29-S32 , February 2007

Roundtable Discussion: Targeting Abdominal Obesity to Reduce Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus

References 

  1. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  2. Pocai A, Morgan K, Buettner C, Gutierrez-Juarez R, Obici S, Rossetti L. Central leptin acutely reverses diet-induced hepatic insulin resistance. Diabetes. 2005;54:3182–3189

PII: S0002-9343(06)01364-7

doi: 10.1016/j.amjmed.2006.11.015

The American Journal of Medicine
Volume 120, Issue 2, Supplement 1 , Pages S29-S32 , February 2007

Article Tools